1
|
Li M, Liu L, Liu C, Chen Z, Li W, Li X, Ma X, Zhang Y. Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review. Clin Ther 2024; 46:59-68. [PMID: 37945502 DOI: 10.1016/j.clinthera.2023.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 11/12/2023]
Abstract
PURPOSE To systematically evaluate the safety, dosing regimen, and efficacy of selexipag for pediatric patients with pulmonary hypertension (PH). METHODS A literature search of the electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar was performed from inception through February 28, 2023. Two reviewers independently searched and evaluated the quality of the studies and pooled data when appropriate. Full-text articles of studies of children diagnosed with PH and treated with selexipag were eligible. Pediatric patients with PH were classified into 2 groups: the add-on therapy group, in which selexipag was used as a third therapy in addition to the baseline treatment, and the transition therapy group, in which patients were switched from parenteral prostacyclin analogs to selexipag. FINDINGS Fourteen studies involving 58 pediatric patients with PH were included. All studies were either case reports or case series. Overall, 30 and 28 patients were in the add-on and transition therapy groups, respectively. In both groups, selexipag was initially administered as 50-200 µg twice daily and titrated to a tolerated dosage of 200-1,600 µg twice daily. Prostacyclin analogs were simultaneously weaned for patients in the transition group. In the add-on therapy group, 16 patients (80.0%) were at low risk of the World Health Organization functional class (WHO FC I/II), 12 (76.9%) were at low risk of the 6-minute walk distance (6MWD; >350 m), and 21 (95.5%) were at low risk of the pulmonary vascular resistance index (PVRi; <20 WU/m2). Furthermore, N-terminal pro-brain natriuretic peptide and mean pulmonary arterial pressure were significantly improved. More than 70% of patients experienced common tolerable side effects, such as headache, nausea, and diarrhea. In the transition therapy group, 5 patients (55.6%) were at low risk according to WHO FC I/II, 6 (66.7%) were at low risk according to 6MWD, and 14 (87.5) were at low risk according to PVRi; however, selexipag had no significant effect on their hemodynamic parameters. Additionally, more than 80% of patients experienced no side effects. IMPLICATIONS Selexipag as add-on therapy or for transition from prostacyclin analogs may have a favorable safety profile and potential efficacy for pediatric patients with PH. Further high-quality evidence of the efficacy and safety of selexipag for the treatment of pediatric PH is warranted.
Collapse
Affiliation(s)
- Meng Li
- Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, China
| | - Lin Liu
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China
| | - Cong Liu
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China
| | - Zebin Chen
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China
| | - Weibin Li
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China
| | - Xuejuan Li
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China
| | - Xiaopeng Ma
- Department of General Surgery, Shenzhen Children's Hospital, Shenzhen, China
| | - Yumao Zhang
- Department of Pharmacy, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
| |
Collapse
|
2
|
Travis J, Rothmann M, Thomson A. Perspectives on informative Bayesian methods in pediatrics. J Biopharm Stat 2023; 33:830-843. [PMID: 36710384 DOI: 10.1080/10543406.2023.2170405] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Accepted: 01/15/2023] [Indexed: 01/31/2023]
Abstract
Bayesian methods have been proposed as a natural fit for pediatric extrapolation, as they allow the incorporation of relevant external data to reduce the required sample size and hence trial burden for the pediatric patient population. In this paper we will discuss our experience and perspectives with these methods in pediatric trials. We will present some of the background and thinking underlying pediatric extrapolation and discuss the use of Bayesian methods within this context. We will present two recent case examples illustrating the value of a Bayesian approach in this setting and present perspectives on some of the issues that we have encountered in these and other cases.
Collapse
Affiliation(s)
- James Travis
- Office of Biostatistics, Office of Translational Science, Center for the Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
| | - Mark Rothmann
- Office of Biostatistics, Office of Translational Science, Center for the Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
| | - Andrew Thomson
- Data Analytics and Methods Taskforce, European Medicines Agency, Amsterdam, NL
| |
Collapse
|
3
|
Narwal N, Katyal D, Kataria N, Rose PK, Warkar SG, Pugazhendhi A, Ghotekar S, Khoo KS. Emerging micropollutants in aquatic ecosystems and nanotechnology-based removal alternatives: A review. CHEMOSPHERE 2023; 341:139945. [PMID: 37648158 DOI: 10.1016/j.chemosphere.2023.139945] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 08/16/2023] [Accepted: 08/22/2023] [Indexed: 09/01/2023]
Abstract
There is a significant concern about the accessibility of uncontaminated and safe drinking water, a fundamental necessity for human beings. This concern is attributed to the toxic micropollutants from several emission sources, including industrial toxins, agricultural runoff, wastewater discharges, sewer overflows, landfills, algal blooms and microbiota. Emerging micropollutants (EMs) encompass a broad spectrum of compounds, including pharmaceutically active chemicals, personal care products, pesticides, industrial chemicals, steroid hormones, toxic nanomaterials, microplastics, heavy metals, and microorganisms. The pervasive and enduring nature of EMs has resulted in a detrimental impact on global urban water systems. Of late, these contaminants are receiving more attention due to their inherent potential to generate environmental toxicity and adverse health effects on humans and aquatic life. Although little progress has been made in discovering removal methodologies for EMs, a basic categorization procedure is required to identify and restrict the EMs to tackle the problem of these emerging contaminants. The present review paper provides a crude classification of EMs and their associated negative impact on aquatic life. Furthermore, it delves into various nanotechnology-based approaches as effective solutions to address the challenge of removing EMs from water, thereby ensuring potable drinking water. To conclude, this review paper addresses the challenges associated with the commercialization of nanomaterial, such as toxicity, high cost, inadequate government policies, and incompatibility with the present water purification system and recommends crucial directions for further research that should be pursued.
Collapse
Affiliation(s)
- Nishita Narwal
- University School of Environment Management, Guru Gobind Singh Indraprastha University, Sector 16-C, Dwarka, 110078, New Delhi, India
| | - Deeksha Katyal
- University School of Environment Management, Guru Gobind Singh Indraprastha University, Sector 16-C, Dwarka, 110078, New Delhi, India.
| | - Navish Kataria
- Department of Environmental Sciences, J.C. Bose University of Science and Technology, YMCA, Faridabad, 121006, Haryana, India.
| | - Pawan Kumar Rose
- Department of Energy and Environmental Sciences, Chaudhary Devi Lal University, Sirsa, 125055, Haryana, India
| | - Sudhir Gopalrao Warkar
- Department of Applied Chemistry, Delhi Technological University, Shahbad Daulatpur Village, Rohini, 110042, New Delhi, India
| | - Arivalagan Pugazhendhi
- Emerging Materials for Energy and Environmental Applications Research Group, School of Engineering and Technology, Van Lang University, Ho Chi Minh City, Viet Nam
| | - Suresh Ghotekar
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, Tamil Nadu, India
| | - Kuan Shiong Khoo
- Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan, Taiwan.
| |
Collapse
|
4
|
Collaco JM, Abman SH, Austin ED, Avitabile CM, Bates A, Fineman JR, Freire GA, Handler SS, Ivy DD, Krishnan US, Mullen MP, Varghese NP, Yung D, Nies MK, Everett AD, Zimmerman KO, Simmons W, Chakraborty H, Yenokyan G, Newell‐Sturdivant A, Christensen E, Eyzaguirre LM, Hanley DF, Rosenzweig EB, Romer LH. Kids Mod PAH trial: A multicenter trial comparing mono- versus duo-therapy for initial treatment of pediatric pulmonary hypertension. Pulm Circ 2023; 13:e12305. [PMID: 37915400 PMCID: PMC10617301 DOI: 10.1002/pul2.12305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Accepted: 09/20/2023] [Indexed: 11/03/2023] Open
Abstract
Pulmonary hypertension (PH) is a significant health problem that contributes to high morbidity and mortality in diverse cardiac, pulmonary, and systemic diseases in children. Evidence-based advances in PH care have been challenged by a paucity of quality endpoints for assessing clinical course and the lack of robust clinical trial data to guide pharmacologic therapies in children. While the landmark adult AMBITION trial demonstrated the benefit of up-front combination PH therapy with ambrisentan and tadalafil, it remains unknown whether upfront combination therapy leads to more rapid and sustained clinical benefits in children with various categories of PH. In this article, we describe the inception of the Kids Mod PAH Trial, a multicenter Phase III trial, to address whether upfront combination therapy (sildenafil and bosentan vs. sildenafil alone) improves PH outcomes in children, recognizing that marked differences between the etiology and therapeutic response between adults and children exist. The primary endpoint of this study is WHO functional class (FC) 12 months after initiation of study drug therapy. In addition to the primary outcome, secondary endpoints are being assessed, including a composite measure of time to clinical worsening, WHO FC at 24 months, echocardiographic assessment of PH and quantitative assessment of right ventricular function, 6-min walk distance, and NT-proBNP levels. Exploratory endpoints include selected biomarkers, actigraphy, and assessments of quality of life. This study is designed to pave the way for additional clinical trials by establishing a robust infrastructure through the development of a PPHNet Clinical Trials Network.
Collapse
Affiliation(s)
- Joseph M. Collaco
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Steven H. Abman
- Department of PediatricsChildren's Hospital ColoradoAuroraColoradoUSA
| | - Eric D. Austin
- Department of PediatricsVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Catherine M. Avitabile
- Department of Pediatrics, Children's Hospital of PhiladelphiaUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Angela Bates
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Jeffrey R. Fineman
- Department of PediatricsUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Grace A. Freire
- Department of PediatricsJohns Hopkins All Children's HospitalSt. PetersburgFloridaUSA
| | | | - Dunbar D. Ivy
- Department of PediatricsChildren's Hospital ColoradoAuroraColoradoUSA
| | - Usha S. Krishnan
- Department of Pediatrics, Vagelos College of Physicians and SurgeonsColumbia UniversityNew YorkNew YorkUSA
| | - Mary P. Mullen
- Department of PediatricsBoston Children's HospitalBostonMassachusettsUSA
| | - Nidhy P. Varghese
- Department of Pediatrics, Baylor College of MedicineTexas Children's HospitalHoustonTexasUSA
| | - Delphine Yung
- Department of PediatricsUniversity of Washington School of MedicineSeattleWashingtonUSA
| | - Melanie K. Nies
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Allen D. Everett
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Kanecia O. Zimmerman
- Departments of Biostatistics and Bioinformatics, Department of Pediatrics, Duke Clinical Research InstituteDuke UniversityDurhamNorth CarolinaUSA
| | - William Simmons
- Departments of Biostatistics and Bioinformatics, Department of Pediatrics, Duke Clinical Research InstituteDuke UniversityDurhamNorth CarolinaUSA
| | - Hrishikesh Chakraborty
- Departments of Biostatistics and Bioinformatics, Department of Pediatrics, Duke Clinical Research InstituteDuke UniversityDurhamNorth CarolinaUSA
| | - Gayane Yenokyan
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Allison Newell‐Sturdivant
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Department of Neurology, Johns Hopkins School of MedicineBIOS Clinical Trials Coordinating Center (CTCC)BaltimoreMarylandUSA
| | - Eric Christensen
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Department of Neurology, Johns Hopkins School of MedicineBIOS Clinical Trials Coordinating Center (CTCC)BaltimoreMarylandUSA
| | - Lindsay M. Eyzaguirre
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Department of Neurology, Johns Hopkins School of MedicineBIOS Clinical Trials Coordinating Center (CTCC)BaltimoreMarylandUSA
| | - Daniel F. Hanley
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
- Department of Neurology, Johns Hopkins School of MedicineBIOS Clinical Trials Coordinating Center (CTCC)BaltimoreMarylandUSA
| | - Erika B. Rosenzweig
- Department of Pediatrics, Vagelos College of Physicians and SurgeonsColumbia UniversityNew YorkNew YorkUSA
| | - Lewis H. Romer
- Departments of Pediatrics, Neurology, Anesthesiology and Critical Care Medicine, and BiostatisticsJohns Hopkins University School of MedicineBaltimoreMarylandUSA
| |
Collapse
|
5
|
Humbert M, Sitbon O, Guignabert C, Savale L, Boucly A, Gallant-Dewavrin M, McLaughlin V, Hoeper MM, Weatherald J. Treatment of pulmonary arterial hypertension: recent progress and a look to the future. THE LANCET. RESPIRATORY MEDICINE 2023; 11:804-819. [PMID: 37591298 DOI: 10.1016/s2213-2600(23)00264-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 07/03/2023] [Accepted: 07/06/2023] [Indexed: 08/19/2023]
Abstract
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic science discoveries, randomised controlled trials, studies of real-world data, and the development of clinical practice guidelines, considerable progress has been made in the treatment options and outcomes for patients with PAH, underscoring the importance of seamless translation of information from bench to bedside and, ultimately, to patients. However, PAH still carries a high mortality rate, which emphasises the urgent need for transformative innovations in the field. In this Series paper, written by a group of clinicians, researchers, and a patient with PAH, we review therapeutic approaches and treatment options for PAH. We summarise current knowledge of the cellular and molecular mechanisms of PAH, with an emphasis on emerging treatable pathways and optimisation of current management strategies. In considering future directions for the field, our ambition is to identify therapies with the potential to stall or reverse pulmonary vascular remodelling. We highlight novel therapeutic approaches, the important role of patients as partners in research, and innovative approaches to PAH clinical trials.
Collapse
Affiliation(s)
- Marc Humbert
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France.
| | - Olivier Sitbon
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France
| | - Christophe Guignabert
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France
| | - Laurent Savale
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France
| | - Athénaïs Boucly
- INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France
| | | | - Vallerie McLaughlin
- Department of Internal Medicine, Division of Cardiology, Frankel Cardiovascular Center University of Michigan Medical School, Ann Arbor, MI, USA
| | - Marius M Hoeper
- Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany; Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hanover (BREATH), Hannover, Germany
| | - Jason Weatherald
- Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
6
|
Aras MA, Abreau S, Mills H, Radhakrishnan L, Klein L, Mantri N, Rubin B, Barrios J, Chehoud C, Kogan E, Gitton X, Nnewihe A, Quinn D, Bridges C, Butte AJ, Olgin JE, Tison GH. Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning. J Card Fail 2023; 29:1017-1028. [PMID: 36706977 PMCID: PMC10363571 DOI: 10.1016/j.cardfail.2022.12.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 11/23/2022] [Accepted: 12/25/2022] [Indexed: 01/26/2023]
Abstract
BACKGROUND Pulmonary hypertension (PH) is life-threatening, and often diagnosed late in its course. We aimed to evaluate if a deep learning approach using electrocardiogram (ECG) data alone can detect PH and clinically important subtypes. We asked: does an automated deep learning approach to ECG interpretation detect PH and its clinically important subtypes? METHODS AND RESULTS Adults with right heart catheterization or an echocardiogram within 90 days of an ECG at the University of California, San Francisco (2012-2019) were retrospectively identified as PH or non-PH. A deep convolutional neural network was trained on patients' 12-lead ECG voltage data. Patients were divided into training, development, and test sets in a ratio of 7:1:2. Overall, 5016 PH and 19,454 patients without PH were used in the study. The mean age at the time of ECG was 62.29 ± 17.58 years and 49.88% were female. The mean interval between ECG and right heart catheterization or echocardiogram was 3.66 and 2.23 days for patients with PH and patients without PH, respectively. In the test dataset, the model achieved an area under the receiver operating characteristic curve, sensitivity, and specificity, respectively of 0.89, 0.79, and 0.84 to detect PH; 0.91, 0.83, and 0.84 to detect precapillary PH; 0.88, 0.81, and 0.81 to detect pulmonary arterial hypertension, and 0.80, 0.73, and 0.76 to detect group 3 PH. We additionally applied the trained model on ECGs from participants in the test dataset that were obtained from up to 2 years before diagnosis of PH; the area under the receiver operating characteristic curve was 0.79 or greater. CONCLUSIONS A deep learning ECG algorithm can detect PH and PH subtypes around the time of diagnosis and can detect PH using ECGs that were done up to 2 years before right heart catheterization/echocardiogram diagnosis. This approach has the potential to decrease diagnostic delays in PH.
Collapse
Affiliation(s)
- Mandar A Aras
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | - Sean Abreau
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | - Hunter Mills
- Bakar Computation Health Sciences Institute, University of California, San Francisco, San Francisco, California
| | - Lakshmi Radhakrishnan
- Bakar Computation Health Sciences Institute, University of California, San Francisco, San Francisco, California
| | - Liviu Klein
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | - Neha Mantri
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | - Benjamin Rubin
- Bakar Computation Health Sciences Institute, University of California, San Francisco, San Francisco, California
| | - Joshua Barrios
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | | | - Emily Kogan
- Janssen Pharmaceuticals, Inc, Raritan, New Jersey
| | - Xavier Gitton
- Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
| | | | | | | | - Atul J Butte
- Bakar Computation Health Sciences Institute, University of California, San Francisco, San Francisco, California
| | - Jeffrey E Olgin
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California
| | - Geoffrey H Tison
- UCSF Department of Medicine, Division of Cardiology, San Francisco, California; Bakar Computation Health Sciences Institute, University of California, San Francisco, San Francisco, California; Division of Cardiology, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California.
| |
Collapse
|
7
|
Caccamo M, Harrell FE, Hemnes AR. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension. Pulm Circ 2023; 13:e12271. [PMID: 37554146 PMCID: PMC10405062 DOI: 10.1002/pul2.12271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 07/20/2023] [Accepted: 07/25/2023] [Indexed: 08/10/2023] Open
Abstract
Selection of endpoints for clinical trials in pulmonary arterial hypertension (PAH) is challenging because of the small numbers of patients and the changing expectations of patients, clinicians, and regulators in this evolving therapy area. The most commonly used primary endpoint in PAH trials has been 6-min walk distance (6MWD), leading to the approval of several targeted therapies. However, single surrogate endpoints such as 6MWD or hemodynamic parameters may not correlate with clinical outcomes. Composite endpoints of clinical worsening have been developed to reflect patients' overall condition more accurately, although there is no standard definition of worsening. Recently there has been a shift to composite endpoints assessing clinical improvement, and risk scores developed from registry data are increasingly being used. Biomarkers are another area of interest, although brain natriuretic peptide and its N-terminal prohormone are the only markers used for risk assessment or as endpoints in PAH. A range of other genetic, metabolic, and immunologic markers is currently under investigation, along with conventional and novel imaging modalities. Patient-reported outcomes are an increasingly important part of evaluating new therapies, and several PAH-specific tools are now available. In the future, alternative statistical techniques and trial designs, such as patient enrichment strategies, will play a role in evaluating PAH-targeted therapies. In addition, modern sequencing techniques, imaging analyses, and high-dimensional statistical modeling/machine learning may reveal novel markers that can play a role in the diagnosis and monitoring of PAH.
Collapse
Affiliation(s)
- Marco Caccamo
- Division of CardiologyWVU Heart and Vascular InstituteMorgantownWest VirginiaUSA
| | - Frank E. Harrell
- Department of BiostatisticsVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Anna R. Hemnes
- Division of Allergy, Pulmonary, and Critical Care MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| |
Collapse
|
8
|
Constantine A, Dimopoulos K, Haworth SG, Muthurangu V, Moledina S. Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service. Am J Respir Crit Care Med 2022; 206:758-766. [PMID: 35579610 PMCID: PMC9799107 DOI: 10.1164/rccm.202110-2428oc] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Rationale: Pediatric pulmonary hypertension is an important cause of childhood morbidity and mortality, but there are limited data on the range of associated diseases, contributions of different pulmonary hypertension subtypes, therapeutic strategies, and clinical outcomes in children. Objectives: To report the 20-year experience of a large UK National Pediatric Pulmonary Hypertension Service focusing on epidemiology and clinical outcomes. Methods: Consecutive patients presenting between 2001 and 2021 were included, and survival analysis was performed for incident patients. Measurements and Main Results: Of 1,353 patients assessed, a pulmonary hypertension diagnosis was made in 1,101 (81.4%) patients (51% female, median age, 2.6 [interquartile range, 0.8-8.2] years). The most common form was pulmonary arterial hypertension in 48%, followed by 32.3% with pulmonary hypertension due to lung disease. Multiple contributory causes of pulmonary hypertension were common, with 16.9% displaying features of more than one diagnostic group. The annual incidence of childhood pulmonary hypertension was 3.5 (95% confidence interval [CI], 3.3-3.8) per 1 million children, and the prevalence was 18.1 (95% CI, 15.8-20.4) per 1 million. The incidence was highest for pulmonary hypertension due to lung disease in infancy (15.0 [95% CI, 12.7-17.2] per 1 million per year). Overall, 82.4% patients received pulmonary arterial hypertension therapy, and escalation to triple therapy during follow-up was required in 13.1%. In 970 (88.1%) incident patients, transplant-free survival was 86.7% (95% CI, 84.5-89%) at 1 and 68.6% (95% CI, 64.7-72.6%) at 10 years. Pulmonary hypertension due to left heart disease had the lowest survival (hazard ratio, 2.0; 95% CI, 1.36-2.94; P < 0.001). Conclusions: Clinical phenotypes of pediatric pulmonary hypertension are heterogeneous and overlapping, with clinical phenotypes that evolve throughout childhood. Despite widespread use of pulmonary arterial hypertension therapy, the prognosis remains poor.
Collapse
Affiliation(s)
- Andrew Constantine
- National Pediatric Pulmonary Hypertension Service UK, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, United Kingdom
- Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton and Harefield Hospitals, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
- National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom; and
| | - Konstantinos Dimopoulos
- Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton and Harefield Hospitals, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
- National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom; and
| | - Sheila G. Haworth
- National Pediatric Pulmonary Hypertension Service UK, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, United Kingdom
- University College London Institute of Cardiovascular Science, University College London, London, United Kingdom
| | - Vivek Muthurangu
- University College London Institute of Cardiovascular Science, University College London, London, United Kingdom
| | - Shahin Moledina
- National Pediatric Pulmonary Hypertension Service UK, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, United Kingdom
- University College London Institute of Cardiovascular Science, University College London, London, United Kingdom
| |
Collapse
|
9
|
García Aguilar H, Gorenflo M, Ivy DD, Moledina S, Castaldi B, Ishida H, Cześniewicz P, Kusa J, Miera O, Pattathu J, Weng K, Ablonczy L, Apitz C, Katona M, Kurosaki K, Pulido T, Yamagishi H, Yasuda K, Cisternas G, Goth M, Lippert S, Radomskyj A, Saleh S, Willmann S, Wirsching G, Bonnet D, Beghetti M. Riociguat in children with pulmonary arterial hypertension:the PATENT‐CHILD study. Pulm Circ 2022; 12:e12133. [PMID: 36186721 PMCID: PMC9485817 DOI: 10.1002/pul2.12133] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 07/29/2022] [Accepted: 08/25/2022] [Indexed: 11/07/2022] Open
Abstract
Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT–CHILD (NCT02562235), a multicenter, single‐arm, 24‐week, open‐label, Phase 3 study. Patients aged 6–17 years in World Health Organization functional class (WHO‐FC) I–III treated with stable endothelin receptor antagonists and/or prostacyclin analogs received riociguat equivalent to 0.5–2.5 mg three times daily in adults, as either oral pediatric suspension or tablets, based on bodyweight. Primary outcomes were safety, tolerability, and PK of riociguat. Twenty‐four patients (mean age 12.8 years), 18 of whom were in WHO‐FC II, were enrolled. Adverse events (AEs), mostly mild or moderate, were reported in 20 patients (83%). Four patients (17%) experienced a serious AE; all resolved by study end and two (8%) were considered study‐drug related. Hypotension was reported in three patients and hemoptysis in one (all mild/moderate intensity). Riociguat plasma concentrations in pediatric patients were consistent with those published in adult patients. From baseline to Week 24, mean ± standard deviation increase in 6‐minute walking distance was 23 ± 69 m (n = 19), and mean decrease in NT‐proBNP was –66 ± 585 pg/ml (n = 14). There was no change in WHO‐FC. Two patients experienced clinical worsening events of hospitalization for right heart failure. PK results confirmed a suitable riociguat dosing strategy for pediatric patients with PAH. The data suggest an acceptable safety profile with potential efficacy signals.
Collapse
Affiliation(s)
| | - Matthias Gorenflo
- Department of Pediatric Cardiology and Congenital Cardiology Heidelberg University Medical Centre Heidelberg Germany
| | - D Dunbar Ivy
- Division of Cardiology, Department of Pediatrics University of Colorado School of Medicine, Children's Hospital Colorado Aurora CO USA
| | - Shahin Moledina
- Cardiology Department Great Ormond Street Hospital for Children NHS Foundation Trust London UK
| | - Biagio Castaldi
- Dipartimento di Pediatria, Azienda Ospedaliera di Padova Padova Italy
| | - Hidekazu Ishida
- Department of Pediatrics Osaka University Graduate School of Medicine Osaka Japan
| | - Paweł Cześniewicz
- Department of Pediatric Cardiology, Regional Specialist Hospital, Research and Development Center Wroclaw Poland
| | - Jacek Kusa
- Department of Pediatric Cardiology, Regional Specialist Hospital, Research and Development Center Wroclaw Poland
| | - Oliver Miera
- Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Center, Berlin Germany
| | - Joseph Pattathu
- Department of Pediatric Cardiology and Congenital Cardiology Heidelberg University Medical Centre Heidelberg Germany
| | - Ken‐Pen Weng
- Department of Pediatrics, Congenital Structural Heart Disease Center, Kaohsiung Veterans General Hospital Kaohsiung Taiwan
| | - Laszlo Ablonczy
- Pediatric Cardiac Center, Hungarian Institute of Cardiology Budapest Hungary
| | - Christian Apitz
- Division of Pediatric Cardiology University Children's Hospital Ulm Ulm Germany
| | - Marta Katona
- Department of Pediatrics Albert Szent‐Györgyi Medical Center, University of Szeged Hungary
| | - Kenichi Kurosaki
- Department of Pediatric Cardiology National Cerebral and Cardiovascular Center Osaka Japan
| | - Tomas Pulido
- Clinical Research Department Ignacio Chavez National Heart Institute Mexico City, Mexico
| | | | - Kazushi Yasuda
- Department of Pediatric Cardiology Aichi Children's Health and Medical Center Aichi Japan
| | | | | | | | | | | | | | | | - Damien Bonnet
- M3C‐Necker, Hôpital Necker Enfants malades APHP Université de Paris Paris France
| | - Maurice Beghetti
- Paediatric Cardiology Unit University Hospitals of Geneva Geneva Switzerland
- Centre Universitaire Romand De Cardiologie Et Chirurgie Cardiaque Pédiatrique, Children's University Hospital, University of Geneva and Lausanne Geneva Switzerland
| |
Collapse
|
10
|
Dunn A, Jung D, Bollinger LL, Krams M, Smith BP, Gobburu JVS. Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy. Ther Innov Regul Sci 2022; 56:873-882. [PMID: 35471560 DOI: 10.1007/s43441-022-00411-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 04/07/2022] [Indexed: 11/25/2022]
Abstract
Improving pediatric therapeutic development is a mission of universal importance among health authorities, pharmaceutical companies, academic institutions, and healthcare professionals. Following the passage of legislation in the United States and Europe, we witnessed the most significant advancement yet in pediatric data generation, resulting in added pediatric use information to almost 700 product labels. Tools to accelerate generation of data for the pediatric population are available for use today, and when utilized in accordance with current practices and laws, these tools could increase the amount and timeliness of pediatric information available for clinicians and patients. If we utilize the current laws that allow regulators to incentivize and require evidence generation, apply extrapolation, and utilize modeling and simulation, as well as including adolescents in the pivotal studies alongside adults as appropriate, two strategic goals could be achieved by 2030: (1) reduce the time to pediatric approval by 50%, and (2) renew pediatric labeling information for 15 priority pediatric drugs without patent and/or exclusivity.
Collapse
Affiliation(s)
- Allison Dunn
- Center for Translational Medicine, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA
| | - Dawoon Jung
- Center for Translational Medicine, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA
| | | | - Michael Krams
- Janssen Research & Development, Spring House, PA, USA
| | - Brian P Smith
- Early Development Analytics, Novartis Institutes of Biomedical Research, Cambridge, MA, USA
| | - Jogarao V S Gobburu
- Center for Translational Medicine, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA.
| |
Collapse
|
11
|
Ploegstra MJ, Berger RMF. Prognostic biomarkers in pediatric pulmonary arterial hypertension. Cardiovasc Diagn Ther 2021; 11:1089-1101. [PMID: 34527535 DOI: 10.21037/cdt-20-374] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 04/29/2020] [Indexed: 11/06/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a progressive life-threatening disease of the pulmonary vasculature. Despite the introduction of targeted therapies, prognosis remains poor. In pediatric PAH, reliable prognostic biomarkers are needed to inform clinicians on disease progression and risk of mortality, in order to be able to assess the need for escalation of medical therapy, consider surgical options such as Pott's shunt and listing for (heart)-lung transplantation. This review provides an overview of prognostic biomarkers that are considered to carry potential for the clinical management of pediatric PAH. These include conventional physiological biomarkers [resting heart rate, heart rate variability (HRV), a child's growth], biomarkers of functional status [World Health Organization functional class, 6-minute walk distance (6MWD), parameters derived from cardiopulmonary exercise testing (CPET), daily physical activity level], electrocardiographic biomarkers, circulating serum biomarkers (natriuretic peptides, uric acid, neurohormones, inflammatory markers, and novel circulating biomarkers), and multiple hemodynamic biomarkers and imaging biomarkers [echocardiography and cardiac magnetic resonance (CMR)]. In recent years, many potential prognostic biomarkers have become available for the management of PAH in children. As the available prognostic biomarkers reflect different aspects of the disease process and functional implications, a multi-marker approach appears the most useful for guiding therapy decisions and improve outcome in pediatric PAH.
Collapse
Affiliation(s)
- Mark-Jan Ploegstra
- Center for Congenital Heart Diseases, Department of Pediatric Cardiology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, The Netherlands
| | - Rolf M F Berger
- Center for Congenital Heart Diseases, Department of Pediatric Cardiology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, The Netherlands
| |
Collapse
|
12
|
Hansmann G, Christou H, Koestenberger M, Sallmon H. Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. Eur J Clin Invest 2021; 51:e13571. [PMID: 33834481 DOI: 10.1111/eci.13571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 04/06/2021] [Accepted: 04/07/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Georg Hansmann
- Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany.,The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), Berlin, Germany
| | - Helen Christou
- Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Martin Koestenberger
- The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), Berlin, Germany.,Division of Pediatric Cardiology, Medical University Graz, Graz, Austria
| | - Hannes Sallmon
- The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), Berlin, Germany.,Department of Pediatric Cardiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.,Berlin Institute of Health, Berlin, Germany.,Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany
| |
Collapse
|
13
|
Manolis E, Musuamba FT, Karlsson KE. The European Medicines Agency Experience With Pediatric Dose Selection. J Clin Pharmacol 2021; 61 Suppl 1:S22-S27. [PMID: 34185894 DOI: 10.1002/jcph.1863] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 03/24/2021] [Indexed: 11/07/2022]
Abstract
Getting the right dose regimen for children and adolescents is important but poses great scientific, practical, and ethical challenges. At the same time, the availability of data in adults is a huge advantage and needs to be used optimally when designing studies in children and analyzing pediatric data. Furthermore, the processes of maturation and growth are always key when selecting doses for children. All the above make study adaptations and model-informed approaches imperative for dose exposure-response characterization and dose selection in children. This article summarizes the experience gained in the European Medicines Agency on this topic and proposes some general guiding principles for defining objectives, study designs, and methodology tools for pediatric dose selection.
Collapse
Affiliation(s)
- Efthymios Manolis
- Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands.,Modelling and Simulation Working Party, European Medicines Agency, Amsterdam, The Netherlands
| | - Flora T Musuamba
- Modelling and Simulation Working Party, European Medicines Agency, Amsterdam, The Netherlands.,Federal Agency for Medicines and Health Products - FAMHP, Bruselles, Belgium
| | - Kristin E Karlsson
- Modelling and Simulation Working Party, European Medicines Agency, Amsterdam, The Netherlands.,Swedish Medical Products Agency, Uppsala, Sweden
| |
Collapse
|
14
|
Beghetti M, Berger RMF, Bonnet D, Grill S, Lesage C, Lemarie JC, Ivy DD. Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study. Front Pediatr 2021; 9:681538. [PMID: 34222150 PMCID: PMC8242164 DOI: 10.3389/fped.2021.681538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 05/14/2021] [Indexed: 11/25/2022] Open
Abstract
FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (FUTURE) 3 was a 24-week open-label, prospective, and randomized phase 3 study that assessed the pharmacokinetics of bosentan 2 mg/kg b.i.d. or t.i.d. in children with pulmonary arterial hypertension (PAH). We report findings from a post-hoc analysis that explored the prognostic value of echocardiographic changes during FUTURE 3 in relation to clinical outcomes observed during the 24-week core study and 48-week extension. Patients aged ≥3 months to <12 years (n = 64) received oral doses of bosentan 2 mg/kg b.i.d. or t.i.d. (1:1) for 24 weeks, after which they were eligible to enter the extension with continued bosentan administration. Echocardiographic evaluations were performed at baseline, Week 12, and 24 of the core study via central reading, and analyzed post-hoc for correlation with clinical outcomes (time to PAH worsening, time to death, and vital status). Sixty-four patients were randomized in the core study [median (IQR) age 3.8 (1.7-7.8) years]; and 58 patients (90.6%) entered the 48-week extension. Most of the patients (68.8%) were receiving ≥1 PAH medication at baseline. Echocardiographic changes during the core study were small but with high variability. There were statistically significant associations at Week 24 between worsening of the parameters, systolic left ventricular eccentricity index (LVEIS) and E/A ratio mitral valve flow, and the outcomes of time to death and time to PAH worsening. Additional studies that utilize simple and reproducible echocardiographic assessments are needed to confirm these findings and subsequently identify potential treatment goals in pediatric PAH.
Collapse
Affiliation(s)
- Maurice Beghetti
- Paediatric Cardiology Unit, Children's Hospital, Geneva, Switzerland.,Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatriques, University of Lausanne, Lausanne, Switzerland
| | - Rolf M F Berger
- Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Damien Bonnet
- M3C-Hospital Necker Enfants Malades, Department of Paediatric Cardiology, Université de Paris, Paris, France
| | - Simon Grill
- Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
| | | | | | - D Dunbar Ivy
- Department of Pediatric Cardiology, Children's Hospital Colorado, Denver, CO, United States
| |
Collapse
|
15
|
Ollivier C, Sun H, Amchin W, Beghetti M, Berger RMF, Breitenstein S, Garnett C, Gullberg N, Hassel P, Ivy D, Kawut SM, Klein A, Lesage C, Migdal M, Nije B, Odermarsky M, Strait J, de Graeff PA, Stockbridge N. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. J Am Heart Assoc 2020; 8:e011306. [PMID: 31088189 PMCID: PMC6585335 DOI: 10.1161/jaha.118.011306] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
| | - Haihao Sun
- 2 Food and Drug Administration Silver Spring MD
| | | | - Maurice Beghetti
- 3 Pediatric Cardiology Unit Centre Universitaire de Cardiologie et Chirurgie Cardiaque Pédiatrique University Hospitals of Geneva City of Geneva Switzerland
| | - Rolf M F Berger
- 4 Center for Congenital Heart Diseases Department of Pediatric Cardiology Beatrix Children's Hospital University Medical Center Groningen University of Groningen the Netherlands
| | | | | | | | | | - Dunbar Ivy
- 7 Heart Institute Children's Hospital Colorado University of Colorado School of Medicine Aurora CO
| | - Steven M Kawut
- 8 Perelman School of Medicine University of Pennsylvania Philadelphia PA
| | | | | | - Marek Migdal
- 11 Childrens Memorial Health Institute Warsaw Poland
| | | | - Michal Odermarsky
- 12 Department of Paediatric Cardiology Paediatric Heart Center Lund University and Skåne University Hospital Lund Sweden
| | | | | | | |
Collapse
|
16
|
Rascher W. Off-label-Anwendung – Wie kommen wir zur Evidenz? Monatsschr Kinderheilkd 2020. [DOI: 10.1007/s00112-020-00925-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Said F, Haarman MG, Roofthooft MTR, Hillege HL, Ploegstra MJ, Berger RMF. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children. J Pediatr 2020; 220:139-145. [PMID: 32113658 DOI: 10.1016/j.jpeds.2020.01.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 12/04/2019] [Accepted: 01/02/2020] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To assess the association between serially measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) serum levels and disease severity in children with pulmonary arterial hypertension (PAH), and to assess its predictive value for death or (heart-)lung transplantation. STUDY DESIGN This was a longitudinal cohort study of the Dutch National Network for Pediatric Pulmonary Hypertension conducted between 2003 and 2017. Data on NT-proBNP and disease severity markers (World Health Organization Functional Class [WHO-FC], 6-minute walking distance [6MWD], and tricuspid annular plane systolic excursion [TAPSE]) were collected every 3 to 6 months from 82 children with PAH. The outcome measure was death or (heart-)lung transplantation. Also, NT-proBNP levels over time were compared between survivors and nonsurvivors. RESULTS The median patient age was 8.8 years (IQR, 4.6-13.5 years), and 61% were female. The median duration of follow-up was 4.8 years (IQR, 1.9-10.0 years). At all times during the course of disease, higher NT-proBNP levels were associated with higher WHO-FC (β = 0.526; 95% CI, 0.451-0.600), lower 6MWD z-score (β = -0.587; 95% CI, -0.828 to -0.346), lower TAPSE z-score (β = -0.783; 95% CI, -1.016 to -0.549), and elevated risk of death or (heart-)lung transplantation (hazard ratio 16.61; 95% CI, 7.81-35.33). Compared with survivors, nonsurvivors had NT-proBNP levels that were higher at first measurement and increased exponentially over time (P = .005). Changes in NT-proBNP serum level over time were predictive of outcome. CONCLUSIONS Throughout the disease course of pediatric PAH, serial measurements of NT-proBNP are associated with disease severity and transplant-free survival. Monitoring NT-proBNP levels over time provides important prognostic information that can support clinical decision making in combination with other established prognostic markers.
Collapse
Affiliation(s)
- Fatema Said
- Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
| | - Meindina G Haarman
- Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Marcus T R Roofthooft
- Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Hans L Hillege
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Mark-Jan Ploegstra
- Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Rolf M F Berger
- Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| |
Collapse
|
18
|
Ivy D, Beghetti M, Juaneda-Simian E, Miller D, Lukas MA, Ioannou C, Okour M, Narita J, Berger RM. A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. THE JOURNAL OF PEDIATRICS: X 2020. [DOI: 10.1016/j.ympdx.2020.100055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
19
|
Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiol Young 2019; 29:1323-1327. [PMID: 31554525 DOI: 10.1017/s104795111900235x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Pulmonary hypertension is a complex and progressive condition that is either idiopathic or heritable, or associated with one or multiple health conditions, with or without congenital or acquired cardiovascular disease. Recent developments have tremendously increased the armamentarium of diagnostic and therapeutic approaches in children and young adults with pulmonary hypertension that is still associated with a high morbidity and mortality. These modalities include non-invasive imaging, pharmacotherapy, interventional and surgical procedures, and supportive measures. The optimal, tailored diagnostic and therapeutic strategies for pulmonary hypertension in the young are rapidly evolving but still face enormous challenges: Healthcare providers need to take the patient's age, development, disease state, and family concerns into account when initiating advanced diagnostics and treatment. Therefore, there is a need for guidance on core and advanced medical training in paediatric pulmonary hypertension. The Association for European Paediatric and Congenital Cardiology working group "pulmonary hypertension, heart failure and transplantation" has produced this document as an expert consensus statement; however, all recommendations must be considered and applied in the context of the local and national infrastructure and legal regulations.
Collapse
|